University of Queensland researchers who mapped cancer cell "neighborhoods" in the most common type of lung cancer have found ...

This is a "landmark study" for cancer immunotherapy and circadian medicine, researcher say ...

Patients with advanced lung cancer who received immunochemotherapy before 15:00 (3 p.m.) had a more delayed disease ...

Survivors of non-small cell lung cancer are at risk for both second primary lung cancers as well as non-lung secondary ...

Frontline: Surgery to remove the tumor is often considered, sometimes followed by chemotherapy or radiation to reduce ...

A deep-learning serial CT biomarker improves survival prediction in immunotherapy-treated NSCLC and outperforms RECIST. Find ...

A 25-year study led by the Barcelona Institute for Global Health finds that PM2.5 increases the risk of all lung cancer subtypes, while several gaseous pollutants are associated with non-small-cell ...

An international team confirms in a pioneering phase 3 clinical trial the decisive role of the time of day on the success of anti-tumour immunotherapies. Huang, Z., Zeng, L., Ruan, Z. et al.

The most robust evidence to date shows that people with a type of lung cancer lived longer if they received immunotherapy before 3pm ...

Robert Brown, 81, says the trial has been like a "light at the end of the tunnel." ...

Observational study finds more pathologic nodal upstaging with more nodes sampled ...

Breakthrough research presented at the 2026 Society of Thoracic Surgeons Annual Meeting shows that additional lymph node ...